Download PDF
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0044-1785461
Case Report

Therapeutic Response to PRRNT in a Rare Case of Metastatic Renal Neuroendocrine Carcinoma

Saumya Sara Sunny
1   Department of Nuclear Medicine, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
,
Julie Hephzibah
2   Department of Medical Oncology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
,
Raju Titus Chacko
2   Department of Medical Oncology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
,
Thomas Alex Kodiatte
3   Department of Pathology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Neuroendocrine tumors (NETs) are a rare spectrum of neoplasms that are characterized by neuroendocrine and neural differentiation. The treatment can be challenging in view of the heterogeneity in differentiation and behavior. Primary renal origin NETs are rare and only a few cases have been reported in the literature. There is limited knowledge on their presentation and response to various lines of treatment. We report a case of a patient with a metastatic renal NET from a rare histological subtype of large cell neuroendocrine carcinoma, known to cause aggressive disease with poor prognosis. A multimodality treatment approach was followed. In spite of surgical management and second-line chemotherapy, the disease progressed. The patient subsequently received peptide receptor radionuclide therapy (PRRNT) using lutetium-177 DOTATATE, following which the patient demonstrated a remarkable clinical and radiological response and is stable to date. In a rare tumor with poor prognosis, the relevance of theranostics and the efficacy of targeted therapies like PRRNT are noteworthy.

Keywords

neuroendocrine tumors - peptide receptor radionuclide therapy - theranostics - lutetium-177 - DOTATATE

Authors' Contribution

S.S.S. contributed to the planning, acquisition of data, literature search, reporting, and interpretation of data. H.J. contributed to the conception and design, acquisition and interpretation of data, guide, and review of the manuscript. K.T.A. contributed to data collection, technical support, review of manuscript, and critical revision, provided guidance. C.R. contributed to the review of the manuscript and critical revision and provided guidance.




Publication History

Article published online:
09 April 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kim JY, Hong S-M, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29 (29) 11-16
    CrossrefPubMedGoogle Scholar
  • 2 DeLellis RA, Osamura RY. Neuroendocrine tumors: an overview. AJSP Rev Rep 2006; 11: 229-234
    Google Scholar
  • 3 Lane BR, Jour G, Zhou M. Renal neuroendocrine tumors. Indian J Urol 2009; 25 (02) 155-160
    CrossrefPubMedGoogle Scholar
  • 4 Romero FR, Rais-Bahrami S, Permpongkosol S, Fine SW, Kohanim S, Jarrett TW. Primary carcinoid tumors of the kidney. J Urol 2006; 176 (6, Pt 1): 2359-2366
    CrossrefPubMedGoogle Scholar
  • 5 Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2016; 70 (01) 93-105
    CrossrefPubMedGoogle Scholar
  • 6 Lane BR, Chery F, Jour G. et al. Renal neuroendocrine tumours: a clinicopathological study. BJU Int 2007; 100 (05) 1030-1035
    CrossrefPubMedGoogle Scholar
  • 7 Martignoni G, Pea M, Brunelli M. et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 2004; 17 (12) 1455-1463
    CrossrefPubMedGoogle Scholar
  • 8 Kim B, Kim H-S, Moon KC. Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki-67 index and mitosis. Diagn Pathol 2019; 14 (01) 12
    CrossrefPubMedGoogle Scholar
  • 9 Bodei L, Weber WA. Somatostatin receptor imaging of neuroendocrine tumors: from agonists to antagonists. J Nucl Med 2018; 59 (06) 907-908
    CrossrefPubMedGoogle Scholar
  • 10 van Essen M, Krenning EP, Kam BLR, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009; 5 (07) 382-393
    CrossrefPubMedGoogle Scholar
  • 11 Hasteh F, Pu R, Michael CW. A metastatic renal carcinoid tumor presenting as breast mass: a diagnostic dilemma. Diagn Cytopathol 2007; 35 (05) 306-310
    CrossrefPubMedGoogle Scholar
  • 12 Korkmaz T, Seber S, Yavuzer D, Gumus M, Turhal NS. Primary renal carcinoid: treatment and prognosis. Crit Rev Oncol Hematol 2013; 87 (03) 256-264
    CrossrefPubMedGoogle Scholar
  • 13 Rinke A, Müller H-H, Schade-Brittinger C. et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27 (28) 4656-4663
    CrossrefPubMedGoogle Scholar
  • 14 Capello A, Krenning EP, Breeman WAP, Bernard BF, de Jong M. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 2003; 44 (01) 98-104
    PubMedGoogle Scholar
  • 15 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 16 Shimbori M, Osaka K, Kawahara T. et al. Large cell neuroendocrine carcinoma of the kidney with cardiac metastasis: a case report. J Med Case Rep 2017; 11 (01) 297
    CrossrefPubMedGoogle Scholar